Shares of Jordan-based Hikma Pharmaceuticals (LSE: HIK) were down 8.2% at 1,795 pence mid-morning after it revealed receipt of a complete response letter (CRL) from the US Food and Drug Administration in relation to its Abbreviated New Drug Application (ANDA) for VR315, its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder).
The drug is delivered using UK-based Vectura Group’s (LSE: VEC) proprietary dry powder inhaler and formulation technology, with Vectura’s shares also falling by 9.3% to 131.60 pence on the news. Vectura is due to receive an $11 million milestone payment on approval of the ANDA plus a mid-teen percentage royalty on net sales of VR315 in the USA, which the company says it now does not expect to occur in 2017.
The FDA has categorized the CRL as ‘Major.’ Hikma and Vectura are in the process of reviewing the response and will provide an update on its application as soon as practicable once it has completed its review of the CRL and discussed this with the FDA. Based on the initial assessment, no material issues were raised regarding the substitutability of the proposed device, the companies said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze